Substituted cycloalkyl P1′ hepatitis C virus inhibitors
申请人:Campbell Jeffrey Allen
公开号:US06878722B2
公开(公告)日:2005-04-12
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Hepatitis C virus inhibitors are disclosed having the general formula:
wherein R
1
, R
2
, R
3
, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors are disclosed having the general formula:
wherein R
1
, R
2
, R
3
, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.